The large shareholder in SLA who is utilising Solagran products including Reopren has increased order sizes, demand in New Zealand is strengthening as patients whose families have a history of alzheimers embrace the treatment. Few potential patients are ware of this treatment at this time.
Sales are at $3500 per course and increasing.
This information came from one of the purchasers.
DYOR
IMOO
- Forums
- ASX - By Stock
- SLA
- new zealand sales
new zealand sales
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online